What Are the Risks of Mounjaro, and How Serious Are They?

What the trial data and regulators say about how often side effects occur

Mounjaro's safety profile was established across the SURMOUNT clinical programme, which randomised thousands of adults with obesity across multiple trials before UK licensing. The most commonly reported events were gastrointestinal: in SURMOUNT-1, nausea affected around 30% of participants at the 15mg dose and vomiting around 16%, with most events rated mild or moderate in severity. Diarrhoea, constipation, indigestion and burping appeared at lower frequencies. These figures matter because they shift the question from "could this happen?" to "how likely is it, and will it pass?", and for the majority of people, the answer is that GI effects do ease. You can read the full breakdown of reported frequencies in the Mounjaro Summary of Product Characteristics on the eMC, which is the authoritative reference for licensed UK dosing and safety data.

The MHRA granted Mounjaro a Black Triangle (▼) designation, which means it is subject to additional monitoring beyond the standard post-market programme. That is not a sign that the medicine is unusually dangerous (many newly licensed treatments carry the mark) but it does mean the regulator is actively reviewing incoming real-world data. Our Mounjaro overview page covers how this monitoring works in practice.

Serious risks: what to watch for and when to call for help

Serious adverse events are uncommon, but dismissing them would be wrong. Acute pancreatitis is the most clinically significant risk the regulator has highlighted for GLP-1 and dual-agonist medicines. In January 2026 the MHRA published a Drug Safety Update specifically addressing this: patients should seek urgent medical attention for severe, persistent abdominal pain that radiates to the back, with or without vomiting. The symptom pattern matters because it can be mistaken for ordinary GI discomfort at first. The Yellow Card reporting scheme allows patients and healthcare professionals to report suspected adverse reactions directly to the MHRA; if you experience anything unexpected on Mounjaro, reporting it contributes to the evidence base that keeps the medicine's labelling current.

Other risks requiring prompt medical contact include signs of a severe allergic reaction (facial swelling, breathing difficulty, rapid onset rash), symptoms suggesting gallbladder problems (pain in the upper right abdomen, particularly after eating), significant dehydration from persistent vomiting or diarrhoea, and any changes in mood or thoughts of self-harm. For a more granular look at the full range of reported effects, our page on the most serious side effects of Mounjaro goes through each category in clinical terms. If you are ever unsure, the safest step is to contact a healthcare professional the same day, not to wait it out.

Risks that depend on your personal history

Not every risk applies equally to everyone, which is why the prescribing assessment exists. A history of pancreatitis, medullary thyroid carcinoma, or multiple endocrine neoplasia type 2 (MEN2) means Mounjaro is contraindicated, the prescriber will not issue a prescription. Certain other conditions, including gallbladder disease and diabetic retinopathy, require careful discussion rather than an automatic rule-out. Mounjaro is not recommended during pregnancy, while breastfeeding, or for anyone planning to conceive; women taking oral contraceptives should add a non-oral method for the first four weeks of treatment and for four weeks after each dose increase, because gastric slowing can reduce pill absorption. These are the kinds of details a real clinician works through with you, not a checklist a website can substitute for. Our prescribers at the nume clinical team discuss suitability and these specific risks as part of every consultation. A broader look at who the medicine is and is not suitable for is on our Mounjaro risks page.

Managing risk: what you can actually do

Most GI side effects can be reduced by eating smaller portions, moving away from high-fat meals, staying well hydrated, and giving each new dose a few days to settle. Rushing through the titration schedule does not help, the dose ladder exists partly to reduce the severity of early side effects, and your prescriber sets the pace based on your response. If you are weighing up how the risk profile compares to everyday side-effect patterns, the detailed breakdown on our Mounjaro side effects page is a useful reference. Practical questions about what changes when you stop (including rebound effects) are addressed on our page about coming off Mounjaro.

At nume, every prescription is preceded by a same-day clinical review by a GPhC-registered Independent Prescriber. Once treatment is approved, it is dispatched the same day for free next-working-day DPD delivery, your pen arrives in plain, unbranded packaging, with tracking to your phone. If a side effect concerns you between consultations, our aftercare team is available seven days a week. Questions about longer-term risks are covered on our page about Mounjaro's long-term side effects. If you are ready to discuss your individual risk profile with a prescriber, check your eligibility through a free consultation.